Compare ORRF & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORRF | OBX |
|---|---|---|
| Founded | 1919 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 861.1M |
| IPO Year | 1995 | 2026 |
| Metric | ORRF | OBX |
|---|---|---|
| Price | $44.33 | $13.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $45.75 | $39.00 |
| AVG Volume (30 Days) | 80.1K | ★ 341.9K |
| Earning Date | 10-20-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 182.43 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $37,144,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $32.55 | $11.52 |
| 52 Week High | $44.30 | $39.00 |
| Indicator | ORRF | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 44.92 |
| Support Level | $40.74 | $11.84 |
| Resistance Level | N/A | $18.21 |
| Average True Range (ATR) | 1.07 | 1.05 |
| MACD | 0.34 | 0.39 |
| Stochastic Oscillator | 88.45 | 64.29 |
Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.